Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021

Rhea-AI Summary

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, will release its first quarter 2021 financial results on May 13, 2021, before U.S. markets open. A conference call will be held at 8:30 AM ET to discuss the results and provide an update. Investors can join via telephone or through a live webcast on Compugen's website. The company is advancing its lead candidate, COM701, an anti-PVRIG antibody for solid tumors, which is currently in a Phase 1 clinical study, alongside COM902, targeting TIGIT.

Positive

• Scheduled release of Q1 2021 financial results on May 13, indicating ongoing operations.
• Lead product candidate, COM701, is undergoing Phase 1 clinical study, expands potential market.
• COM902 is also in Phase 1, diversifying the therapeutic pipeline.

Negative

• None.

HOLON, Israel, May 3, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2021 financial results on Thursday, May 13, 2021 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. Compugen's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.  

Investor Relations contact:
John Mullaly
Managing Director
LifeSci Advisors, LLC
Email: jmullaly@lifesciadvisors.com    
Tel: +1 (617) 429-3548

 

 

 

 

 

View original content:http://www.prnewswire.com/news-releases/compugen-to-release-first-quarter-2021-results-on-thursday-may-13-2021-301281952.html

SOURCE Compugen Ltd.

FAQ

When will Compugen release its financial results for Q1 2021?

Compugen will release its Q1 2021 financial results on May 13, 2021.

What time is the Compugen conference call for Q1 2021 results?

The conference call for Compugen's Q1 2021 results will be at 8:30 AM ET on May 13, 2021.

What are the main drug candidates being developed by Compugen?

Compugen is developing COM701, an anti-PVRIG antibody, and COM902, targeting TIGIT, both currently in Phase 1 clinical studies.

How can investors access Compugen's conference call?

Investors can access Compugen's conference call via telephone or through a live webcast on the company's website.

Is Compugen publicly traded, and what is its ticker symbol?

Yes, Compugen is publicly traded under the ticker symbol CGEN on Nasdaq.